A Single-Arm, Open Label, 16-week Extension Study to Evaluate the Efficacy and Safety of a Second Course of a Digital Therapeutic as an Adjunct to Standard of Care Antipsychotic Therapy in Adult and Late Adolescent Participants With Experiential Negative Symptoms of Schizophrenia
- NCT06067984
- PHASE3
- INTERVENTIONAL
Last updated: 2024-02-20
Purpose of Trial
Click Therapeutics Study App is an interactive, software-based intervention for experiential negative symptoms of schizophrenia.
The purpose of the proposed OLE study is to evaluate the maintained efficacy and safety of a second consecutive course of Click Therapeutics Study App as an adjunct treatment to standard of care (SOC) in participants who were on the Study App and have recently completed the Click Therapeutics Randomized Clinical Trial.
This study is for people with
Schizophrenia
Negative Symptoms in Schizophrenia
Interventions being studied
Study App
Inclusion Criteria:
A participant will be eligible for entry into the study if all the following criteria are met:
* Completed participation in NCT05853900 (Week 20) study within 7 days of the extension study Baseline Visit (Day 1).
* Is the sole user of an iPhone with an iPhone operating system (iOS) 14 or greater or a smartphone with an Android operating system (OS) 10 or greater and is willing to download and use the specified Study App required by the protocol.
* Is willing and able to receive SMS text messages and push messages on their smartphone.
* It is the owner of, and has regular access to, an email address.
* Has regular access to the Internet via cellular data plan and/or wi-fi.
* Had stable housing during NCT05853900, with no anticipated housing changes during the duration of this study.
Exclusion Criteria:
A participant will not be eligible for study entry if any of the following criteria are met:
* Has not completed the Week 16 Visit (Day 112) in the NCT05853900 study.
* Has a positive urine drug screening or participant self-reports use of synthetic cathinones (bath salts), synthetic cannabinoids (K2, Spice), inhalants, amphetamines (including MDMA/ecstasy), phencyclidine (PCP), cocaine, opiates, benzodiazepines, barbiturates, hallucinogens, or parenteral drugs. Participants with a positive urine drug test and/or recreational use of THC will not be excluded from the study at the discretion of the investigator. Participants with a positive urine drug screen (UDS) or self-report who have a valid prescription for barbiturates, benzodiazepines, or opiates will not be excluded from the study at the discretion of the investigator.
* Has suicidal ideation or behavior, as assessed by the C-SSRS:
1. Participants with a "yes" response to either Items 4 or 5 on the C-SSRS Suicidal Ideation Item during the NCT05853900 study.
2. Participants with a "yes" response on the C-SSRS Suicidal Behavior Items within the last 6 months (26 weeks) prior to or at the Baseline Visit
* Participants who, in the opinion of the investigator, present a serious risk of suicide.
ELIGIBILITY
Gender: ALL
Age: 18+
Healthy Volunteers: No
Location
Primary Contact(s)
Boehringer Ingelheim
Data obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Learn more at
ClinicalTrials.gov
